Melanotan II | 30 mg pen

Melanotan II is a peptide positioned for controlled research settings where melanocortin receptor signaling is being studied in relation to melanogenesis and pigmentation endpoints, central appetite/energy-balance readouts, and sexual arousal pathway activation.

Supports

1. Melanocyte cAMP signaling and tyrosinase-linked melanogenesis (MC1R models)
2. Pigment distribution and eumelanin/photoprotection endpoints in skin systems
3. Hypothalamic melanocortin tone in feeding-behavior paradigms (MC3R/MC4R)
4. Libido/arousal pathway activation readouts in neuroendocrine models
5. Inflammation/oxidative-stress signaling markers influenced by melanocortin pathways (model-dependent)

Description

Melanotan II is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) developed as a melanocortin receptor agonist for experimental research on pigmentation biology and neuroendocrine regulation. In controlled settings, it is commonly investigated for its ability to stimulate melanogenesis through melanocortin signaling in melanocytes and related pigment-cell models.

Beyond peripheral pigmentation endpoints, Melanotan II is also studied for central melanocortin activity—particularly in pathways associated with appetite regulation and sexual arousal—where MC3R/MC4R signaling is used as a mechanistic lens. Reported outcomes vary by model, receptor subtype involvement, and study design.

Melanotan II is not positioned as a therapeutic agent on Peptoora and is presented for research context only, where receptor pharmacology, pigment outcomes, and behavioral endpoints can be evaluated under defined experimental controls.

Clinical Status

Melanotan II has been evaluated in human studies focused on pigmentation outcomes and has also appeared in observational and case-based medical literature related to non-medical exposure. A substantial portion of mechanistic understanding is derived from animal and in vitro models characterizing melanocortin receptor signaling and downstream melanogenesis or neurobehavioral endpoints. It is not approved for therapeutic use.

Evidence type:
Human RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

Melanotan II acts as an agonist across melanocortin receptor subtypes, with prominent research emphasis on MC1R-mediated melanocyte signaling. In melanocytes, MC1R activation is associated with increased intracellular cAMP, upregulation of melanogenic enzymes (including tyrosinase), and downstream increases in melanin production, supporting pigmentation and photoprotection research endpoints.

Central effects are commonly studied through MC3R/MC4R signaling in hypothalamic circuits, where melanocortin tone is linked to feeding behavior, energy balance, and arousal-related pathways. Its cyclic peptide structure is often discussed as contributing to receptor affinity and in vivo stability relative to native α-MSH, although kinetics and receptor selectivity remain model- and assay-dependent.

Benefits

• Stimulation of Melanogenesis and Skin Pigmentation:
  Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), studied for its ability to activate the melanocortin-1 receptor (MC1R) in melanocytes. This receptor activation increases melanin synthesis, resulting in a gradual darkening of skin tone. Research indicates enhanced UV protection through elevated eumelanin levels, supporting investigations into photoprotection and pigmentation modulation.
• Enhanced UV Protection and Skin Health:
  By promoting natural melanin production, Melanotan II enhances cellular defense against ultraviolet damage. Studies demonstrate that increased melanin density helps absorb harmful UV radiation and reduce oxidative DNA damage in skin cells. This protective mechanism makes it a valuable subject in research related to skin photoprotection and anti-aging dermatology.
• Appetite and Energy Regulation Through MC4R Pathways:
  Melanotan II also acts on the melanocortin-4 receptor (MC4R) within the hypothalamus, influencing appetite control and energy balance. Preclinical studies show reductions in caloric intake and fat accumulation, suggesting its role in experimental research on metabolic regulation, obesity, and neuroendocrine energy homeostasis.
• Improved Libido and Sexual Function:
  Research on Melanotan II has demonstrated a strong influence on sexual arousal and erectile function through central melanocortin receptor activation (particularly MC3R and MC4R). It stimulates pathways associated with libido and reproductive behavior in both male and female models, leading to its recognition as a subject of interest in sexual function research.
• Neuroprotective and Mood-Enhancing Effects:
  Studies suggest that Melanotan II exerts neuroprotective and mood-modulating actions through the melanocortin system’s influence on dopamine and serotonin pathways. This neuroendocrine activity may contribute to improved mood stability, motivation, and stress resilience, making it a focus of investigation in neuropeptide research.
• Reduction of Inflammation and Oxidative Stress:
  Melanocortin activation by Melanotan II leads to suppression of pro-inflammatory cytokines such as TNF-α and IL-1β, along with enhanced antioxidant enzyme activity. These combined effects provide systemic anti-inflammatory protection, supporting research in inflammatory regulation, wound recovery, and cellular stress adaptation.
• Potential Support for Metabolic Optimization:
  By influencing hypothalamic signaling and lipid metabolism, Melanotan II may contribute to increased energy expenditure and improved insulin sensitivity. This has led to growing research interest in its metabolic regulatory effects, particularly in models examining obesity, glucose tolerance, and lipid homeostasis.
• Synergy in Photoprotection and Skin Repair Research:
  When combined with peptides such as GHK-Cu or BPC-157, Melanotan II enhances outcomes in experimental skin health and regenerative protocols. The synergistic stimulation of melanogenesis and collagen synthesis supports advanced studies in dermatological recovery and post-inflammatory hyperpigmentation control.
• Long-Lasting Pigmentation Maintenance:
  Melanotan II provides prolonged melanin retention even after cessation of administration, attributed to its stable receptor binding and extended activation of melanogenic pathways. This makes it ideal for research into long-term pigmentation stability and protective adaptation against environmental stressors.
• Exploration in Neuroendocrine and Behavioral Pathways:
  Beyond pigmentation and libido research, Melanotan II is studied for its central nervous system regulatory effects via the melanocortin network. Its influence on reward circuits, satiety, and emotional regulation suggests wider potential for understanding neuroendocrine integration and behavioral modulation mechanisms.
• 
  

Research Data

Stack Suggestions

In extended experimental designs, Melanotan II is sometimes paired with:

• PT-141 (Bremelanotide) → to compare melanocortin-linked arousal signaling across different agonist profiles
• GHK-Cu → to co-study skin biology endpoints (matrix, repair signaling) alongside pigmentation readouts
• Glutathione (reduced) → to explore pigmentation/oxidative-stress coupling in redox-focused skin models

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

Melanotan II may cause side effects, although these do not occur in all research subjects. Most common adverse reactions are transient and typically subside as the subject adapts to the compound. It is crucial to start with the lowest possible dose to gauge subject tolerance.

Nausea and Vomiting: This is the most frequently reported initial side effect, especially when higher doses are introduced rapidly. Nausea is often mild to moderate and tends to decrease over the first week of administration.

Facial Flushing/Warmth: Subjects may experience a temporary sensation of warmth and redness in the face or body shortly after injection. This is often linked to transient changes in blood pressure.

Appetite Suppression: Consistent with the MC4R agonism, a noticeable reduction in appetite and food cravings is common, which may lead to weight loss over longer research cycles.

Hyperpigmentation of Moles/Freckles: Existing moles or freckles may darken faster and become more pronounced than the surrounding skin. Researchers should document all dermatological changes carefully.

Injection Site Reactions: As with any SubQ injection, minor redness, swelling, or irritation may occur at the injection site.

Spontaneous Erections (Male Subjects): Due to the potent MC4R activity, male subjects may experience unexpected and prolonged erections during the initial research phase.

It is important to emphasize that most side effects of Melanotan II are dose-dependent, reversible, and manageable with careful dose titration.

Scientific References

• Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study Human RCT
• Melanotan II user experience: a qualitative study of online discussion Observational
• Melanotan II injection resulting in systemic toxicity and rhabdomyolysis Observational
• Melanotan II: a possible cause of renal infarction: review of the literature and case report Observational
• Evidence that melanocortin receptor agonist melanotan-II synergistically augments the ability of naltrexone to blunt binge-like ethanol intake in male C57BL/6J mice Animal
• Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the internet In vitro
• Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide In vitro
• Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers Human RCT
• Melanotan II – an overview Animal
• A glimpse into the underground market of melanotan Observational
• Case report melanotan tanning injection: a rare cause of priapism Observational
• Melanotan | Actas dermo-sifiliográficas In vitro
• 
  

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.